Gut health business Microba Life Sciences Ltd (ASX:MAP) has successfully listed on the Australian Securities Exchange in an IPO that raised A$30 million with assistance from Thomson Geer.

Microba provides microbiome testing services and is developing therapies to treat chronic diseases such as inflammatory bowel disease. The company operates in the emerging US$4.89 billion gut microbiome sector.

The Thomson Geer team was led by Partner Emma Cook who said: “We were pleased to have been able to help Microba list on the ASX and enable investors to support its work in human health.”

Thomson Geer advised Microba on all aspects of the listing including legal requirements in relation to the prospectus and the due diligence process.

Microba’s world-leading technology that measures the human gut microbiome was developed at the University of Queensland by founders Professor Philip Hugenholtz and Professor Gene Tyson. It is tapping into a growing body of research demonstrating that the gut microbiome plays a central role in health and disease.

The Microba board includes Professor Ian Frazer, the co-inventor of the technology that led to Gardasil, the leading vaccine to prevent cervical cancer.

The IPO was backed by New York Stock Exchange-listed synthetic biology company Ginkgo Bioworks, which is backed by Bill Gates.

The Thomson Geer team included Emma Cook, Senior Associate Belinda Pinnow and Lawyer Robin Mahly.

‍